Literature DB >> 19270533

ABCG2-mediated DyeCycle Violet efflux defined side population in benign and malignant prostate.

Grinu Mathew1, Earl A Timm, Paula Sotomayor, Alejandro Godoy, Viviana P Montecinos, Gary J Smith, Wendy J Huss.   

Abstract

The efflux of Hoechst 33342 by ATP-binding cassette protein G2 (ABCG2) membrane pump allows reproducible identification of a subpopulation of cells by flow cytometric analysis termed the "side population" (SP). The SP identified by constitutive Hoechst efflux contains the stem/progenitor cell population from bone marrow and many solid organs, including prostate. DyeCycle Violet (DCV) is a cell membrane permeable, fluorescent vital dye that intercalates into DNA and is a substrate for ABCG2-mediated efflux. Therefore, DCV was evaluated in this study as a tool for identification of the SP from prostate cancer cell lines and from freshly harvested human prostate tissue. SPs that demonstrated ABCG2-mediated efflux of DCV were identified in the human prostate cancer cell lines CWR-R1, DU-145 and RWPE-1, but not in the BPH-1, LAPC-4 or PC-3 cell lines. Additionally, a SP was identified in enzymatically disaggregated prostate tumors from Transgenic Adenocarcinoma of Mouse Prostate (TRAMP), human benign prostate tissue and human prostate cancer tissue. The causal role of ABCG2-mediated efflux of DCV in the identification of the SP was confirmed by loss of the SP by incubation with the specific inhibitor of ABCG2, Fumitremorgin C. Expression of ABCG2 in the SP cells was confirmed by qRT-PCR and immunofluorescence analysis. Consequently, DCV represents an important new tool for isolation of viable candidate stem cells/cancer stem cells as a SP from cultured prostate cell lines, and prostate tissue specimens, without the requirement for instrumentation with ultra-violet excitation capability and minimizing the risk of damage to DNA in the sorted population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19270533      PMCID: PMC2848479          DOI: 10.4161/cc.8.7.8043

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  43 in total

1.  Distinct progenitor populations in skeletal muscle are bone marrow derived and exhibit different cell fates during vascular regeneration.

Authors:  Susan M Majka; Kathyjo A Jackson; Kirsten A Kienstra; Mark W Majesky; Margaret A Goodell; Karen K Hirschi
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

2.  Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo.

Authors:  Sheng Zhou; John J Morris; Yuxiao Barnes; Lubin Lan; John D Schuetz; Brian P Sorrentino
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-06       Impact factor: 11.205

3.  ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport.

Authors:  J Klucken; C Büchler; E Orsó; W E Kaminski; M Porsch-Ozcürümez; G Liebisch; M Kapinsky; W Diederich; W Drobnik; M Dean; R Allikmets; G Schmitz
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

Review 4.  SP analysis may be used to identify cancer stem cell populations.

Authors:  Annamaria Hadnagy; Louis Gaboury; Raymond Beaulieu; Danuta Balicki
Journal:  Exp Cell Res       Date:  2006-09-09       Impact factor: 3.905

Review 5.  ABC transporters as phenotypic markers and functional regulators of stem cells.

Authors:  Kevin D Bunting
Journal:  Stem Cells       Date:  2002       Impact factor: 6.277

6.  The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype.

Authors:  S Zhou; J D Schuetz; K D Bunting; A M Colapietro; J Sampath; J J Morris; I Lagutina; G C Grosveld; M Osawa; H Nakauchi; B P Sorrentino
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

7.  Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population.

Authors:  Bryan E Welm; Stacey B Tepera; Teresa Venezia; Timothy A Graubert; Jeffrey M Rosen; Margaret A Goodell
Journal:  Dev Biol       Date:  2002-05-01       Impact factor: 3.582

8.  Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material.

Authors:  Julio E Diestra; George L Scheffer; Isabel Català; Marc Maliepaard; Jan H M Schellens; Rik J Scheper; Jose R Germà-Lluch; Miguel A Izquierdo
Journal:  J Pathol       Date:  2002-10       Impact factor: 7.996

9.  Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model.

Authors:  Paula J Kaplan-Lefko; Tsuey-Ming Chen; Michael M Ittmann; Roberto J Barrios; Gustavo E Ayala; Wendy J Huss; Lisette A Maddison; Barbara A Foster; Norman M Greenberg
Journal:  Prostate       Date:  2003-05-15       Impact factor: 4.104

Review 10.  CD34- hematopoietic stem cells: current concepts and controversies.

Authors:  Yalin Guo; Michael Lübbert; Monika Engelhardt
Journal:  Stem Cells       Date:  2003       Impact factor: 6.277

View more
  27 in total

1.  Constant Degradation of the Androgen Receptor by MDM2 Conserves Prostate Cancer Stem Cell Integrity.

Authors:  Premkumar Vummidi Giridhar; Karin Williams; Andrew P VonHandorf; Paul L Deford; Susan Kasper
Journal:  Cancer Res       Date:  2019-01-09       Impact factor: 12.701

2.  Substrate affinity of photosensitizers derived from chlorophyll-a: the ABCG2 transporter affects the phototoxic response of side population stem cell-like cancer cells to photodynamic therapy.

Authors:  Janet Morgan; Jennifer D Jackson; Xiang Zheng; Suresh K Pandey; Ravindra K Pandey
Journal:  Mol Pharm       Date:  2010-09-01       Impact factor: 4.939

3.  The Efflux Transporter ABCG2 Maintains Prostate Stem Cells.

Authors:  Neha G Sabnis; Austin Miller; Mark A Titus; Wendy J Huss
Journal:  Mol Cancer Res       Date:  2016-11-17       Impact factor: 5.852

4.  Identification of drug-resistant subpopulations in canine hemangiosarcoma.

Authors:  A Khammanivong; B H Gorden; A M Frantz; A J Graef; E B Dickerson
Journal:  Vet Comp Oncol       Date:  2014-08-11       Impact factor: 2.613

5.  Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs.

Authors:  Linda S Steelman; Stephen L Abrams; John G Shelton; William H Chappell; Jörg Bäsecke; Franca Stivala; Marco Donia; Ferdinando Nicoletti; Massimo Libra; Alberto M Martelli; James A McCubrey
Journal:  Cell Cycle       Date:  2010-04-15       Impact factor: 4.534

6.  Harnessing the DNA Dye-triggered Side Population Phenotype to Detect and Purify Cancer Stem Cells from Biological Samples.

Authors:  Maximilian Boesch; Elisabeth Hoflehner; Dominik Wolf; Guenther Gastl; Sieghart Sopper
Journal:  J Vis Exp       Date:  2017-05-10       Impact factor: 1.355

7.  The identification and validation of Trichosstatin A as a potential inhibitor of colon tumorigenesis and colon cancer stem-like cells.

Authors:  Tse-Hung Huang; Szu-Yuan Wu; Yan-Jiun Huang; Po-Li Wei; Alexander Th Wu; Tsu-Yi Chao
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

8.  Isolation of side population cells from endometrial cancer cells using a violet laser diode.

Authors:  Satoshi Tomiyasu; Tomoyuki Miyamoto; Michihiro Mori; Takahiro Yaguchi; Hiromasa Yakushiji; Setsuyo Ohno; Yasuyuki Miyake; Takuya Sakaguchi; Masatsugu Ueda; Eiji Ohno
Journal:  Hum Cell       Date:  2013-10-04       Impact factor: 4.174

9.  Flow cytometric detection of the classical hodgkin lymphoma: clinical and research applications.

Authors:  Mikhail Roshal; Brent L Wood; Jonathan R Fromm
Journal:  Adv Hematol       Date:  2010-11-28

10.  RNA binding protein RBM3 increases β-catenin signaling to increase stem cell characteristics in colorectal cancer cells.

Authors:  Anand Venugopal; Dharmalingam Subramaniam; Julia Balmaceda; Badal Roy; Dan A Dixon; Shahid Umar; Scott J Weir; Shrikant Anant
Journal:  Mol Carcinog       Date:  2015-08-31       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.